

Edgar Filing: HAEMONETICS CORP - Form SC 13G

HAEMONETICS CORP  
Form SC 13G  
June 11, 2009

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
Rule 13d-102

Under the Securities Exchange Act of 1934  
(Amendment No. \_\_\_)\*

Haemonetics Corp

-----  
(Name of Issuer)

Common

-----  
(Title of Class of Securities)

405024100

-----  
(CUSIP Number)

06/10/2009

-----  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which  
this Schedule is filed:

- Rule 13d-1 (b)
- Rule 13d-1 (c)
- Rule 13d-1 (d)

-----  
\* The remainder of this cover page shall be filled out for a reporting  
person's initial filing on this form with respect to the subject class of  
securities, and for any subsequent amendment containing information which  
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be  
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange  
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of  
the Act but shall be subject to all other provisions of the Act (however, see  
the Notes).

Page 1 of 7 Pages

CUSIP No. 405024100

-----  
(1) Names of reporting persons.

Neuberger Berman Group LLC

-----  
(2) Check the appropriate box if a member of a group (see instructions) (a)   
(b)

-----  
(3) SEC use only.  
-----

Edgar Filing: HAEMONETICS CORP - Form SC 13G

(4) Citizenship or place of organization.

Delaware

-----  
Number of shares beneficially owned by each reporting person with:

(5) Sole voting power:  
3225

(6) Shared voting power:  
2571979

(7) Sole dispositive power:  
0

(8) Shared dispositive power:  
3047604

-----  
(9) Aggregate amount beneficially owned by each reporting person.

3047604

-----  
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions).

-----  
(11) Percent of class represented by amount in Row 9.

11.892%

-----  
(12) Type of reporting person (see instructions).

HC

-----  
Page 2 of 7 Pages

CUSIP No. 405024100

-----  
(1) Names of reporting persons.

Neuberger Berman LLC

-----  
(2) Check the appropriate box if a member of a group (see instructions) (a)   
(b)

-----  
(3) SEC use only.

-----  
(4) Citizenship or place of organization.

Delaware

-----  
Number of shares beneficially owned by each reporting person with:

(5) Sole voting power:  
3225

(6) Shared voting power:  
2571979

Edgar Filing: HAEMONETICS CORP - Form SC 13G

(7) Sole dispositive power:  
0

(8) Shared dispositive power:  
3047604

-----  
(9) Aggregate amount beneficially owned by each reporting person.

3047604

-----  
(10) Check if the aggregate amount in Row (9) excludes certain shares  (see instructions).

-----  
(11) Percent of class represented by amount in Row 9.

11.892%

-----  
(12) Type of reporting person (see instructions).

BD IA

-----  
Page 3 of 7 Pages

CUSIP No. 405024100

-----  
(1) Names of reporting persons.

Neuberger Berman Management LLC

-----  
(2) Check the appropriate box if a member of a group (see instructions) (a)   
(b)

-----  
(3) SEC use only.

-----  
(4) Citizenship or place of organization.

Delaware

-----  
Number of shares beneficially owned by each reporting person with:

(5) Sole voting power:  
0

(6) Shared voting power:  
2571979

(7) Sole dispositive power:  
0

(8) Shared dispositive power:  
2571979

-----  
(9) Aggregate amount beneficially owned by each reporting person.

2571979

-----  
(10) Check if the aggregate amount in Row (9) excludes certain shares

Edgar Filing: HAEMONETICS CORP - Form SC 13G

(see instructions).

(11) Percent of class represented by amount in Row 9.

10.036%

(12) Type of reporting person (see instructions).

BD IA

Page 4 of 7 Pages

CUSIP No. 405024100

(1) Names of reporting persons.

Neuberger Berman Equity Funds

(2) Check the appropriate box if a member of a group (see instructions) (a)   
(b)

(3) SEC use only.

(4) Citizenship or place of organization.

Delaware

Number of shares beneficially owned by each reporting person with:

(5) Sole voting power:  
0

(6) Shared voting power:  
2560479

(7) Sole dispositive power:  
0

(8) Shared dispositive power:  
2560479

(9) Aggregate amount beneficially owned by each reporting person.

2560479

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions).

(11) Percent of class represented by amount in Row 9.

9.991%

(12) Type of reporting person (see instructions).

IV

Page 5 of 7 Pages

## Edgar Filing: HAEMONETICS CORP - Form SC 13G

Item 1(a). Name of Issuer:

Haemonetics Corp

Item 1(b). Address of Issuer's Principal Executive Offices:

400 Wood Rd.  
Braintree, MA 02184

Item 2(a). Name of Person Filing:

Neuberger Berman Group LLC  
Neuberger Berman LLC  
Neuberger Berman Management LLC  
Neuberger Berman Equity Funds

Neuberger Berman Group LLC ("NBG") makes this filing on behalf of itself and its direct and indirect affiliates, including, Neuberger Berman Holdings LLC, formerly known as Neuberger Berman Inc. ("NBI"). NBI and its subsidiaries, Neuberger Berman LLC and Neuberger Berman Management LLC, became subsidiaries of NBG following the sale of certain assets formerly owned by Lehman Brothers Holdings Inc.

Please note that in connection with sale described above, certain disclosures required under Section 13(d) of the Securities Exchange Act of 1934, as amended, that were filed by NBI under SEC Central Index Key (CIK) number (#0001068144) will now be filed under NBG's CIK number (#0001465109).

This statement is filed by: (i) Neuberger Berman Group LLC with respect to shares of the issuer's common stock ("Shares"), beneficially owned by Neuberger Berman LLC and certain affiliated persons; (ii) Neuberger Berman LLC with respect to Shares beneficially owned by certain affiliated persons; (iii) and Neuberger Berman Management LLC with respect to Shares beneficially owned by certain affiliated persons.

Neuberger Berman Group LLC, Neuberger Berman LLC and Neuberger Management LLC have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

Item 2(b). Address or Principal Business Office or, If None, Residence:

605 Third Avenue  
New York NY 10158

Item 2(c). Citizenship:

Delaware

Item 2(d). Title of Class of Securities:

Common

Item 2(e). CUSIP No.:

Edgar Filing: HAEMONETICS CORP - Form SC 13G

405024100

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e)  An investment adviser in accordance with ss. 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with ss. 240.13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(c), check this box.

Item 4. Ownership

- (a) Amount beneficially owned:  
3047604 (1)
- (b) Percent of class:  
11.892
- (c) Number of shares as to which such person has:
  - (i) Sole power to direct the vote  
3225
  - (ii) Shared power to direct the vote  
2571979
  - (iii) Sole power to dispose or direct the disposition of  
0
  - (iv) Shared power to dispose or direct the disposition of  
3047604

Item 5. Ownership of 5 Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date

## Edgar Filing: HAEMONETICS CORP - Form SC 13G

hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

### Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

Neuberger Berman Group LLC may be deemed to be a beneficial owner of securities for purposes of Rule 13d-3 because certain affiliated persons have shared power to retain or dispose of, and in some cases the sole power to vote, the securities of many unrelated clients. Neuberger Berman Group LLC or its affiliated persons do not, however, have any economic interest in the securities of those clients. The clients are the actual owners of the securities and have the sole right to receive and the power to direct the receipt of dividends from or proceeds from the sale of such securities. No one client has an interest of more than 5% of the issuer.

With regard to the Shares set forth under item 4(c)(II), Neuberger Berman Group LLC may be deemed to be the beneficial owner for purposes of Rule 13d-3 because certain affiliated persons have shared power to retain, dispose of and vote the securities. Each of Neuberger Berman LLC and Neuberger Berman Management LLC serve as a sub-adviser and investment manager, respectively, of Neuberger Berman Group LLC's various registered mutual funds which hold such Shares in the ordinary course of their business and not with the purpose nor with the effect of changing or influencing the control of the issuer. The holdings of Neuberger Berman Fixed Income LLC and NB Alternative Fund Management LLC, affiliates of Neuberger Berman LLC, are also aggregated to comprise the holdings referenced herein.

It should be further noted that the Share calculation under item 4(c)(IV) is derived from a total combination of the Shares set forth under Item 4(c)(I and II). The remaining balance of Shares, if any, are for the individual client accounts over which Neuberger Berman LLC has shared power to dispose but not vote Shares.

### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

N/A

### Item 8. Identification and Classification of Members of the Group.

N/A

### Item 9. Notice of Dissolution of Group.

N/A

### Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Edgar Filing: HAEMONETICS CORP - Form SC 13G

-----  
1. Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management LLC and certain affiliated persons own directly no Shares. As investment advisers, certain affiliated persons that are controlled by Neuberger Berman Group LLC have investment and voting powers with respect to the Shares held.

Neuberger Berman Group LLC, through its direct and indirect subsidiary Neuberger Berman Holdings LLC, controls Neuberger Berman LLC and certain affiliated persons. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, Neuberger Berman Group LLC may be deemed to own beneficially 3,047,604 Shares while Neuberger Berman LLC and Neuberger Berman Management LLC may be deemed to own beneficially 3,047,604 Shares and 2,571,979 Shares constituting approximately 11.892% and 10.036%, respectively, of the Shares outstanding. Each of Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management LLC and certain affiliated persons disclaim beneficial ownership of any of the securities covered by this statement.

Page 6 of 7 Pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Neuberger Berman Group LLC

Date: 06/10/2009

/s/ Kevin Handwerker  
Name: Kevin Handwerker  
Title: General Counsel

Neuberger Berman LLC

Date: 06/10/2009

/s/ Kevin Handwerker  
Name: Kevin Handwerker  
Title: General Counsel

Neuberger Berman Management LLC

Date: 06/10/2009

/s/ Robert Conti  
Name: Robert Conti  
Title: President

Neuberger Berman Equity Funds

Date: 06/10/2009

/s/ Robert Conti  
Name: Robert Conti  
Title: President and Chief  
Executive Officer

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, Provided, however, That a power of attorney for this purpose



Edgar Filing: HAEMONETICS CORP - Form SC 13G

which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

ATTENTION: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). (Secs. 3(b), 13(d)(1), 13(d)(2), 13(d)(5), 13(d)(6), 13(g)(1), 13(g)(2), 13(g)(5), 23, 48 Stat. 882, 894, 901; sec. 203(a), 49 Stat. 704; sec. 8, 49 Stat. 1379; sec. 10, 78 Stat. 88a; sec. 2, 82 Stat. 454; secs. 1, 2, 84 Stat. 1497; secs. 3, 10, 18, 89 Stat. 97, 119, 155; secs. 202, 203, 91 Stat. 1494, 1498, 1499; (15 U.S.C. 78c(b), 78m(d)(1), 78m(d)(2), 78m(d)(5), 78m(d)(6), 78m(g)(1), 78m(g)(2), 78m(g)(5), 78w)) [43 FR 18499, Apr. 28, 1978, as amended at 43 FR 55756, Nov. 29, 1978; 44 FR 2148, Jan. 9, 1979; 44 FR 11751, Mar. 2, 1979; 61 FR 49959, Sept. 24, 1996; 62 FR 35340, July 1, 1997; 63 FR 2867, Jan. 16, 1998; 63 FR 15287, Mar. 31, 1998]

Page 7 of 7 Pages